Active, not recruitingPhase 2NCT04207944
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
Studying Intraductal papillary mucinous carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Duke University
- Principal Investigator
- Peter Allen, MDDuke University
- Intervention
- Sulindac 400 MG(drug)
- Enrollment
- 100 target
- Eligibility
- 21-85 years · All sexes
- Timeline
- 2020 – 2026
Study locations (4)
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Memorial Sloan Kettering, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
Collaborators
Johns Hopkins University · Massachusetts General Hospital · Memorial Sloan Kettering Cancer Center · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04207944 on ClinicalTrials.govOther trials for Intraductal papillary mucinous carcinoma of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07216521Intent of Surgery for IPMNNYU Langone Health
- RECRUITINGNCT07117045Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic CancerChanghai Hospital
- RECRUITINGNCT06574373Identification of New Theranostic Biomarkers of Pancreatic Tumor ProgressionFondazione Policlinico Universitario Agostino Gemelli IRCCS
- ACTIVE NOT RECRUITINGNANCT06712797Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception CenterH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06694792Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) ConsortiumIRCCS San Raffaele
- ENROLLING BY INVITATIONNCT06276764The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)Adenocyte, LLC
- RECRUITINGNCT06638866AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening CohortChanghai Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT06519097Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)H. Lee Moffitt Cancer Center and Research Institute
See all trials for Intraductal papillary mucinous carcinoma of pancreas →